Author Topic: (Abst.) PACTRIMS 2019: Trial of in-home natalizumab infusions  (Read 50 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 8282
  • MS diagnosed 1980
  • Location: Pacific Northwest
(Abst.) PACTRIMS 2019: Trial of in-home natalizumab infusions
« on: February 05, 2019, 08:23:32 pm »
Biogen funded this study, presented at the 2019 PACTRIMS (Pan-Asian Committee on Treatment and Research in MS)  conference, trying out in-home infusions of natalizumab:


MS Treatment: Other Drugs


Patients’ Perspectives on a Changed Model of Care from Out-patients to The Home for the Infusion of Natalizumab
Juaton MS1, Cusack L1, Schultz TJ1, Thomas A2, Georgiou P3, Simon L3, Naidoo K4, Webb K5, Karnon J6, Ravindran J5
1Adelaide Nursing School, University of Adelaide, Adelaide, Australia 5005; 2Post Op Care at Home (Pty Ltd), McLaren Vale, Australia 5171; 3Ambulatory Care Day Unit, Royal Adelaide Hospital, Adelaide, Australia 5005; 4Biogen Australia and New Zealand, North Ryde, Australia 2113; 5Neurology Department, Royal Adelaide Hospital, Adelaide, Australia 5005; 6School of Public Health, University of Adelaide, Adelaide, Australia 5005
Conflict of interest: The research was Funded by Biogen Australia and New Zealand as investigator initiated research. Ms Anne Thomas is Director of Post-Op Care At Home (Pty Ltd). This organisation was sub-contracted to deliver the home care nursing. Ms Kerisha Naidoo is an employee of Biogen.


Background: This paper presents the qualitative component of a study on the safety and clinical effectiveness, acceptability and cost effectiveness of home infusions of natalizumab for people with Multiple Sclerosis (MS). We compared the home nursing model of care with the usual care (an out-patient intravenous therapy service) in a randomised cross-over trial that included a qualitative component.


Objective: The objective was to understand the experiences and perspectives of people who have received home infusions using the new model of care.


Methods: This study was conducted using an exploratory descriptive methodology. Twelve of the 37 participants consented for a face-to-face interview. The transcripts were thematically analysed using the Braun and Clark approach.


Results: The outcome from the interviews and analysis revealed eight subthemes, which were grouped into two main themes; ‘the experience’ and ‘convenience’. The findings indicated that being at home while receiving natalizumab infusions offers physical and emotional comfort for MS patients and their family. The benefits of delivering this infusion at home included no travel or car parking costs, no waiting in the hospital and comfort within the home environment. It was an easy and stress free experience for most participants. This study found that MS patients preferred receiving their natalizumab infusions at home.


Conclusion: Patients’ voices must be used to inform patient-centred care. Home infusions of natalizumab are a safe alternative model of care and provide patient benefits such as flexibility, reduced costs and an improved patient experience. These findings should inform future healthcare delivery.
MS Speaks--online for 13 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.

 

Related Topics

  Subject / Started by Replies Last post
0 Replies
58 Views
Last post December 19, 2017, 02:43:17 pm
by agate
0 Replies
46 Views
Last post March 03, 2018, 02:19:02 pm
by agate
0 Replies
38 Views
Last post April 07, 2019, 03:55:02 pm
by agate
0 Replies
1 Views
Last post October 23, 2019, 08:52:52 pm
by agate
0 Replies
2 Views
Last post November 08, 2019, 08:48:05 am
by agate